|
Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA Clinical research trials and Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA. Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA clinical trial. Test subjects typically receive the most expert healthcare available for their Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA  Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA
Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA
For Condition: Cardiovascular Diseases,Heart Diseases,Thrombosis,Coronary Arteriosclerosis,Atherosclerosis,Inflammation
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To examine the associations of common variation in inflammation/thrombosis genes with intermediate quantitative phenotypes and subclinical coronary atherosclerosis in the Coronary Artery Risk Factor Development in Young Adults (CARDIA) Study, a large, bi-racial cohort study.
Details: BACKGROUND: Atherosclerosis is a major determinant of coronary heart disease and is determined by the interplay of genetic and environmental risk factors. Although atherosclerosis tends to aggregate in families, it does not exhibit classical Mendelian segregation. Thus, the genes that determine an individual's risk of atherosclerosis likely involve multiple sites within genes and interactions between genes, all of which define a genetic risk that is modified by the host environment. DESIGN NARRATIVE: The genetic epidemiology study examines the associations of common variation in inflammation/thrombosis genes with intermediate quantitative phenotypes and subclinical coronary atherosclerosis in the Coronary Artery Risk Factor Development in Young Adults (CARDIA) Study, a large, bi-racial cohort study. The set of 25 candidate genes involve pathways (cytokines, chemokines, and their receptors; cellular adhesion molecules; and, coagulation proteins) and include several receptor-ligand pairs. Using cladistic analysis and the resources of the Program in Genomic Applications (PGA), the investigators will identify a limited set of single nucleotide polymorphisms (range 3-10 SNPs per gene) that characterize common haplotypes in these candidate genes within persons of African descent and European descent. DNA from the CARDIA Year 10 examination (n = 3,950 subjects) will be genotyped for the selected variants that characterize the common haplotypes. Data on the presence of common variants and haplotypes will be incorporated into the CARDIA Study database. Levels of two important intermediate phenotypes, fibrinogen and C-reactive protein (CRP) were previously determined. Non-invasive assessment of coronary atherosclerosis, defined as the presence of coronary artery calcification (CAC), was obtained on CARDIA participants at the Year 15 exam. Analyses will be stratified by race/ethnicity and focus on the associations of the common haplotypes with fibrinogen, CRP, and CAC measured in early adult life. Secondarily, the investigators will explore possible gene-gene and gene-environment interactions. The proposed multi-disciplinary collaboration should enhance the sensitivity and specificity of efforts to assess the associations of common variation in sets of inflammation/thrombosis candidate genes and cardiovascular risk in young adults.
Eligibility:
Study Type: Observational, Natural History, Defined Population
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidSiscovick, , University of Washington
Additional Information:
Study ID Numbers: 1186;
Study Start Date: August 2002
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046605
Other Cardiovascular Diseases Studies:
1. A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters
2. Inflammation Markers Over Time in Cardiovascular Disease
3. Genetic Architecture of Plasma T-PA and PAI-1
4. Dose Finding And Efficacy Study Of Angiomax In Infants Under Six Months With Thrombosis
5. Alfimeprase for thrombolysis in Acute Peripheral Arterial Occlusion
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA
|
|
|
|
|
|
|
|
